Intranasal Administration for Targeting Neurodegenerative Disorders

The Blood-Brain Barrier (BBB) limits the ability of therapeutic molecules to reach the brain following oral or parenteral administration. The nasal delivery system has the potential to be used for drug delivery due to its ease of administration and increased bioavailability. This approach to brain targeting has shown great promise and is useful in treating a range of illnesses linked to dysfunctional brain function. This, along with drug elimination and inactivation during the drug's journey in the systemic circulation and hepatic metabolism, reduces the effectiveness of treatment, necessitates high drug dosages, and frequently results in unfavorable side effects. The anatomical benefits of the nasal route, which allow for the direct delivery of drugs from the nasal cavity to the brain and avoid the blood-brain barrier, are the driving force behind this developing discipline. In addition to playing a significant role in the pathophysiology of neurodegenerative illnesses, oxidative stress can also play a significant role in the damage caused by cerebral ischemia and apoptosis. An interesting new development in medicine is the fascinating intersection of medicinal plants, their bioactive constituents, and nanotechnology, which has shown promise in the treatment of various NDDs. Drug concentration in the brain is increased through nose-to-brain delivery, which circumvents the blood-brain barrier and permits the direct movement of therapeutic molecules. 

Keywords: Cerebellomedullary, Nose-to-Brain, Nanoemulsion, Nano phytomedicines.